ArticleEndocrine, metabolic & immune disorders drug targets2026
Comparison of Islet Function in People With Different Glucose Metabolic States.
Article in Endocrine, metabolic & immune disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionType 2 Diabetes Mellitus (T2DM) is closely associated with impaired islet β-cell function. Multiple indicators can be used to evaluate islet function and insulin resistance. The aim of this study is to establish a β-cell function assessment model based on oral glucose tolerance test (OGTT) indices, providing a reference for the early diagnosis and treatment of diabetes.
methodsIn this study, 30 Normal Glucose Tolerance (NGT), 43 Impaired Glucose Regulation (IGR), and 42 T2DM subjects were enrolled. The levels of blood glucose, insulin, c-peptide, and proinsulin were measured during OGTT. Insulinogenic index (IGI), C-Peptide generation Index (CPI), and proinsulinogenic index (PNI) were calculated. Fasting-state ratios, including c-peptide to glucose (CP/I), proinsulin to insulin (PI/I), and proinsulin to c-peptide (PI/CP), were calculated. The area under the curve (AUC) was analyzed for these indices and their corresponding ratios. ROC curve analysis was performed to evaluate the diagnostic value of these indicators for glucose metabolism disorders and β-cell function.
resultsIn the fasting state, CP/I gradually increased, while IGI and PNI gradually decreased from the NGT group to the IGR and T2DM groups. For diagnosing IGR, the AUCs of CP/I, IGI, and PNI were 0.8101, 0.762, and 0.7605; for T2DM, they were 0.8746, 0.9651, and 0.8451; and for distinguishing IGR from T2DM, they were 0.7054, 0.8200, and 0.6833, respectively. DISCUSSION: Different indicators have different diagnostic capabilities for IGR and T2DM. The comparison of various indicators reveals pancreatic islet function across different glucose-metabolizing populations.
conclusionCP/I, IGI, and PNI were more sensitive in reflecting impaired glucose tolerance. CP/I can reflect insulin clearance capacity, and IGI can reflect β-cell dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.